Leadership
Our team of passionate biopharmaceutical leaders combines deep expertise in drug development and commercialization.
Meet our leadership teamPipeline
We have one of the largest and most diverse pipelines in rare disease.
Explore our pipelineLatest news
View more news >Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome
Rare perspective
Insights and information on our approach to collaborating with rare disease communities, supporting our teammates at Ultragenyx, and developing new therapies for rare disease
Read our blog >